The ipilimumab plus nivolumab combination was also approved for advanced renal cell carcinoma [11], microsatellite instability-high/mismatch repair-deficient (MSI-H/dMMR) metastatic colorectal carcinoma [12], hepatocellular carcinoma [13], and metastatic non-small cell lung cancer (NSCLC) in case the tumor cells express PD-L1 (≥ 1%) [14] or regardless of PD-L1 expression [15], and for unresectable malignant pleural mesothelioma [16]. This evidence concerns the gene CD274 and neoplasm.